Potential health hazard — use of or exposure to this product may cause temporary or medically reversible adverse health consequences.
Ranitidine 150 mg tablets Recalled by AAA Pharmaceutical, Inc. Due to CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API
What You Should Do
Stop using this product immediately. Do not consume, use, or distribute it.
Return the product to the place of purchase for a full refund. If you have questions, contact AAA Pharmaceutical, Inc. directly.
Affected Products
Ranitidine 150 mg tablets, 24 count bottles, NDC 37808-196-01.
Quantity: 34,272 (24-count bottles)
Why Was This Recalled?
CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API
Where Was This Sold?
Product was distributed to one consignee who may have distributed the product further to their retail stores.
About AAA Pharmaceutical, Inc.
AAA Pharmaceutical, Inc. has 4 total recalls tracked by RecallDetector.
Related Recalls
Icosapent Ethyl Capsules Recalled by Zydus Pharmaceuticals (USA) Inc Due to Failed Tablet/Capsule specifications: Red dots inside capsule and...
Zydus Pharmaceuticals (USA) Inc · March 9, 2026
Product label: Temozolomide Capsules Recalled by Rising Pharma Holding, Inc. Due to Failed Impurities/Degradation Specifications: An out-of-specification result observed during...
Rising Pharma Holding, Inc. · March 3, 2026
Semaglutide Inj. Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report